WASHINGTON DC, July 29 Athera Biotechnology announced theAward from NACB (National Academy of Clinical Biochemistry) for DistinguishedAbstracts at the annual AACC (American Association of Clinical Chemistry)meeting in Washinton DC was awarded to Athera Biotechnology founder JohanFrostegard and his colleagues. The abstract was one of 26 selected for theaward, among over 700 accepted abstracts. Winners will be honored at NACBAward luncheon held at the AACC meeting on July 30.
Frostegard's abstract describes a study where low levels of antibodiesagainst phosphorylcholine (anti-PC) were measured using an enzyme linkedimmunoassay (ELISA) by CVDefine(TM), a new kit developed by Athera. Thefindings indicate that low levels of IgM anti-PC are associated with anincreased risk of cardiovascular disease (CVD) in a population. Frostegardand colleagues conclude that low levels of anti-PC could be a novel riskmarker for CVD and ischemic stroke, especially in men.
Athera Biotechnologies AB develops novel products for risk assessment andtreatment of CVD. The company was founded in 2002 to exploit findings made byProfessors Johan Frostegard and Ulf de Faire on the critical role ofphospholipid antibodies (aPL) in the inflammatory process of cardiovasculardisease. Athera is based in Karolinska Institutet Science Park in Stockholmand main investors include Karolinska Development and Baltic Sea Foundation.Athera is also a major partner in the highly ranked EU-project CVDIMMUNE leadby Karolinska Institutet. The project involves 10 academic and industrialpartners, including Phadia GmbH, Johannes Gutenberg-University Mainz andLeiden University Medical Center.
SOURCE Athera Biotechnologies AB